Besides, several studies confirm that ovarian cancer-associated MSCs enhance chemoresistance in ovarian cancer in multiple ways, including platelet-derived growth factor signaling, bone morphogenetic protein 4/hedgehog signaling loop, and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway (15–17). This evidence concerns the gene AKT1 and ovarian carcinoma.